Medivation (MDVN) Misses Q1 EPS by 10c

Go back to Medivation (MDVN) Misses Q1 EPS by 10c

Leerink Partners Reit OP Rating Following Medivation (MDVN) 1Q Results

May 8, 2015 9:45 AM EDT

Leerink Partners maintains an Outperform rating on Medivation, Inc. (NASDAQ: MDVN), with their price target set at $128. Leerink believes that the demand for Xtandi appears to be solid, and expects a continued uptake of Xtandi over the rest of the year. MDVN reported US Xtandi sales were $224M in 1Q15. While this was in the... More

Medivation (MDVN) PT Lifted at UBS Despite Q1 'Miss'

May 8, 2015 9:40 AM EDT

UBS analyst Matthew Roden reiterated a Buy rating and boosted his price target on Medivation (NASDAQ: MDVN) to $142.00 (from $130.00) despite a miss on US Xtandi sales by $14m. The firm remain encouraged by the results since only nominal double-digit growth is required to beat 2015... More